$69.99
0.00 (0%)
ImClone Systems, Inc. (IMCL.DL)
CAPS Rating:
A biopharmaceutical company which advances oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.
No one has written a Pitch for IMCL.DL stock yet. Tell us why you think IMCL.DL will outperform or underperform the S&P 500.
RSS Headlines
Fool UK
